Company profilePharmaceutical#411 of 1,318 in Pakistan✓ No DRAP alerts

BROOKES PHARMACEUTICAL LABORATORIES (PAK.) LTD.

Pharmaceutical company · 39 brands · 59 molecules

Ranked #52 of 156 companies in Antianemic, Iron Preparations

39 registered products 18 pharmaceutical brands 59 distinct molecules 0 DRAP alerts

Company overview

39
registered products
18
pharmaceutical brands
59
distinct molecules
12
therapeutic classes
0
DRAP alerts

BROOKES PHARMACEUTICAL LABORATORIES (PAK.) LTD. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 39 product registrations across 59 distinct molecules. Its portfolio is concentrated in Antianemic, Iron Preparations and Angiotensin-Ii Antagonists, Combinations. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Top molecules by brand count

Therapeutic classes

Antianemic, Iron Preparations · 2Angiotensin-Ii Antagonists, Combinations · 1Psycholeptics; Antipsychotics, Anxiolytics, Hypnotics And Sedatives · 1Cardiac Therapy · 1Cough Expectorant · 1Other Nervous System Drugs · 1Antipsoriatics · 1Antidepressants · 1Preparations For Wounds And Ulcers · 1Anti-Parkinson Drugs · 1Neuro · 1Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 1

Conditions treated

Parkinson'S Disease · 1Liver/Kidney/Stone · 1

Price band (DRAP official ceilings)

Registered products priced by source
DVAGO4 products · Rs 500 – Rs 1,200
Servaid2 products · Rs 210 – Rs 406.8
Median across source: Rs 718.74

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Get the full profile for BROOKES

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.